ZS Pharma, Inc. is a privately held specialty pharmaceutical company located in Ft. Worth, TX and focused on the development and commercialization of proprietary oral sorbent technology.  Our compound, known as zirconium silicate (ZrSi), selectively removes life-threatening toxins in patients suffering from kidney and liver disease and related conditions.  We have secured exclusive intellectual property and intend to pursue multiple indications to address significant, poorly-met medical conditions (acute and chronic hyperkalemia, hyperammonemia, hyperphosphatemia).  We have conducted compelling in vitro and in vivo studies and have hired a highly diverse, seasoned executive team.  

ZS Pharma plans to conduct confirmatory efficacy and safety studies and continue on the path towards commercialization of products developed from the ZrSi technology platform.  The primary focus will be on our lead product candidate, ZS-9, a novel, non-systemic oral sorbent designed for the treatment of hyperkalemia, a serious condition resulting from elevated serum potassium levels. The company intends to initiate human clinical trials of ZS-9 later this year.